Fierce Biotech January 24, 2024
While many companies have spent the years since the COVID-19 pandemic began just hoping to get back on track with the way things were before, Abbott has devised its own definition of the “new normal.”
In its full-year earnings report Wednesday, the medtech tallied year-over-year organic sales growth of 11.6% in its base business for 2023—easily outstripping not only the “high single-digit” rate it had predicted at the start of the year, but also the 7% growth rate it had posted in the two years leading up to 2020, as CEO Robert Ford noted in a call with investors Wednesday morning.
“We exited the pandemic in an even stronger position,” he said. “2023 was a very successful year: We outperformed...
Today's Sponsors
Today's Sponsor
Topics: Medical Devices